At the Extraordinary General Meeting in Oasmia Pharmaceutical AB (the ”company”), held on 20 October 2021, which due to the corona virus has been conducted solely through postal voting pursuant to temporary legislation, the following resolutions were passed. All resolutions were in accordance with the proposals described in detail in the general meeting documents which are available at the company’s website, www.oasmia.com.
Adoption of a long-term incentive program based on employee stock options for senior executives in the company
The Extraordinary General Meeting resolved to adopt a long-term incentive program based on employee stock options for senior executives in the company. The program consists of no more than 4,500,000 options to be allotted during October 2021. The employee stock options entitle, after vesting in accordance with the terms and conditions, the participant to subscribe for shares during the period from and including 1 November 2024 until and including 31 January 2025. Each employee stock option entitles the participant to acquire one share in the company at an exercise price corresponding to 140 percent of the volume-weighted average share price for the company’s share on Nasdaq Stockholm during the 10 trading days immediately preceding 20 October 2021. The right to receive employee stock options shall accrue to Francois Martelet, Fredrik Järrsten, Peter Selin and Heidi Ramstad. The options will be allotted free of charge. The Board of Directors, or a Remuneration Committee appointed within the Board of Directors, shall be responsible for preparing the detailed design and administration of the terms and conditions of the incentive program, in accordance with the above presented terms and guidelines. In connection therewith, the Board of Directors shall be entitled to make adjustments to meet specific foreign regulations or market conditions. The Board of Directors shall also be entitled to make other adjustments if significant changes occur in the company or in its environment that would result in that the adopted terms of the incentive program no longer fulfil their objectives.
For more information:
Francois Martelet, Chief Executive Officer
Phone: +46 18-50 54 40
E-mail: IR@oasmia.com
About Oasmia Pharmaceutical AB
Oasmia is a specialty pharmaceutical company focused on the development of new therapeutic options for patients suffering from hard-to-treat cancers. It has an emerging pipeline of clinical-stage assets targeting late-stage cancers. Apealea® (paclitaxel micellar) is being made available to ovarian cancer patients through a partnership with Elevar Therapeutics, Inc. Development programs include Cantrixil, in clinical development for late-stage ovarian cancer, and docetaxel micellar, in development for advanced prostate cancer. Oasmia has proprietary drug delivery technology designed to improve solubility, efficacy and safety. Oasmia’s shares are traded on Nasdaq Stockholm (OASM). To find out more about Oasmia please visit www.oasmia.com.